Abbott India share price
NSE: ABBOTINDIABSE: 500488Pharmaceuticals & BiotechnologyMid Cap
Abbott India Limited · Face value ₹10 Face value. The nominal value of one share as the company issued it, the unit its share capital is counted in and a dividend can be stated as a percentage of; it has no link to the share price. Face value in the glossary · Listed Feb 1966
Last close ₹26,275.00up ₹760.00 (2.98%)BSE ₹26,278.90
Share price at the NSE close on 28 Oct 2026. Previous close ₹25,515.00.
28 Oct: open ₹25,515.00, high ₹26,440.00, low ₹25,300.00
52-week range of traded prices to 28 Oct 2026
₹24,650.00Low, 23 Oct 2026₹30,655.00High, 25 Nov 2025
- Next results date: the board meets on 5 Nov 2026 to consider: quarterly results. Results calendar
- Market capMarket capitalisation. Share price times the number of shares: what the whole company is worth at the day's price. The rank is by average market value over the six months to Jun 2026, among listed companies. Market capitalisation: how it is worked out
- ₹55,833 Cr183rd largest listed
- P/EPrice to earnings, trailing. Market cap divided by the profit of the last twelve months (the latest four quarters, or two half years for a company that reports half-yearly) that belongs to the company's own shareholders, after the share of the other owners of its subsidiaries: what investors pay for each rupee of a year's profit. Price to earnings, trailing: how it is worked out
- 34.58
- P/BPrice to book. Market cap divided by the net worth that belongs to the company's own shareholders, its assets less everything it owes and less the other owners' share of its subsidiaries, on its latest balance sheet. Price to book: how it is worked out
- 11.69
- Dividend yieldDividend yield. Dividends paid per share in the twelve months to the day, as a percentage of the day's share price.
- 2.50%
- ROEReturn on equity. Profit over the last twelve months (the latest four quarters, or two half years for a company that reports half-yearly) that belongs to the company's own shareholders, as a percentage of their net worth, the money they have in the business. Net worth is the average of the latest balance sheet and the one a year before it.
- 35.9%
- ROCEReturn on capital employed. Operating profit after depreciation (revenue less operating expenses and depreciation, without other income and one-off items) as a percentage of all the money the business runs on: the whole group's net worth, the other owners of its subsidiaries included, plus borrowings. Lease liabilities are not counted: the results filings do not state them. The profit is over the last twelve months (the latest four quarters, or two half years for a company that reports half-yearly); net worth and borrowings are on the latest balance sheet.
- 39.6%
- Debt to equityDebt to equity. Borrowings divided by the whole group's net worth, the other owners of its subsidiaries included: rupees borrowed for each rupee of equity in the business. Lease liabilities are not counted: the results filings do not state them. From the balance sheet at the end of Mar 2026.
- 0.00
- Volume, NSEVolume. Shares traded on the last trading day; delivery is the part buyers kept rather than sold again the same day. Volume in the glossary
- 5,72755.2% delivered
About Abbott India
Abbott India Limited makes, markets and distributes medicines, sold mainly in India.12 Its customers include distributors, stockists, healthcare professionals, hospitals, government institutions, pharmacists and consumers.3 Its medicines cover gastrointestinal care, women's health, metabolic disorders, the central nervous system, vaccines and other specialties.4
It reports a single business segment, pharmaceuticals.2 It has a plant in Verna, Goa, and offices in Mumbai (BKC and Chembur), Chennai, Hyderabad, Lucknow, Delhi and Nepal.15
It was incorporated in 1944.1 It merged its wholly owned subsidiaries Beem Healthcare Limited and Valencia Pharmaceuticals Limited into itself with an appointed date (the date from which a merger counts) of 1 Jul 1998, and Lenbrook Pharmaceuticals Limited with an appointed date of 1 Oct 2003.67
Abbott Capital India Limited, UK, is its holding company, and Abbott Laboratories, USA, is its ultimate holding company.87 Its managing director is Kartik Rajendran.5
Abbott India key points
Results
- Revenue from operations was ₹6,929 crore in the year to Mar 2026, against ₹6,409 crore a year earlier, a growth of 8.1%; profit before tax was ₹2,079 crore, up 10.2%.9
- EBITDA (earnings before interest, tax, depreciation and amortisation) was ₹2,180 crore and profit after tax ₹1,552 crore in the year to Mar 2026; return on average capital employed (profit earned on the money invested in the business) was 34.50%.10
- The company states 10-year compound annual growth (the average yearly rate) of 9.0% in revenue, 17.0% in EBITDA and 18.8% in profit after tax.11
- Net cash from operating activities was ₹1,319.24 crore in the year to Mar 2026, against ₹1,011.84 crore a year earlier.12
Therapy areas
- Gastrointestinal. The business grew at a double-digit rate in the year to Mar 2026, with brands including Udiliv, Duphalac, Cremaffin Plus, Digene and Creon.13
- Women's health. The business is built around Duphaston and Femoston; the market for dydrogesterone (a progesterone-like hormone) grew slowly and faced lower-priced generic competition, and the business is expanding into fertility, contraception and menopause.14
- Metabolics. The business is built around Thyronorm for thyroid disorders; in the year to Mar 2026 it launched Extensior (semaglutide), a GLP-1 medicine (a class of diabetes medicines) for type 2 diabetes, through an exclusive partnership with Novo Nordisk, priced comparably with local generic semaglutide.151617
- Nervous system, vaccines and others. Vertin, for vertigo, anchors the central nervous system portfolio; the vaccines business sells adult influenza vaccines as the market moves from trivalent to quadrivalent forms; Arachitol drives the multi-specialty portfolio.1819
Where revenue comes from
- Exports were 1.2% of turnover in the year to Mar 2026; the company serves 28 states and 8 union territories in India and 4 other countries: Sri Lanka, Nepal, Maldives and Bhutan.20
Research and development
- In the year to Mar 2026 the company managed 21 clinical studies and contributed to 35 publications in scientific journals.23
- Research and development spending was ₹6.27 crore, 0.09% of turnover, in the year to Mar 2026.24
- It launched 5 new products in the year to Mar 2026, in gastrointestinal, metabolic and women's health medicines.25
What the company expects
- The company stated in its annual report for the year to Mar 2026 that it plans to strengthen its own brands and selectively expand through partnerships and acquisitions, with a focus on adult vaccines, women's health and nervous system medicines.11
- The company stated in its annual report for the year to Mar 2026 that it plans to deepen its presence in Tier 2 and Tier 3 markets (smaller cities and towns) and expects metabolic growth from wider reach for Thyronorm and scaling Extensior.2515
Recent events
- On 11 May 2026, the board recommended a final dividend of ₹525 and a special dividend of ₹131 per share of ₹10, for approval at the annual general meeting of 13 Aug 2026; the company's documents give no outcome.26
- After the government notified 4 new labour codes on 21 Nov 2025, the company recognised an added employee benefit cost of ₹18.10 crore in the year to Mar 2026.27
Litigation and regulatory matters
- As of its annual report of 20 Jul 2026, it was contesting in the Bombay High Court a final demand of ₹3.47 crore, received in the year to Nov 2005, for the Drugs Prices Equalisation Account (a price-control fund).28
- The Bombay High Court stayed recovery of the ₹3.47 crore Drugs Prices Equalisation Account demand against a ₹1.56 crore bank guarantee, and the company has provided ₹1.43 crore against that demand, including interest, against ₹1.39 crore a year earlier.2829
- Tax claims against the company that it does not accept as debts (contingent liabilities: amounts it may or may not have to pay)30
Item Mar 2026 Mar 2025 Income tax ₹85.82 crore ₹82.25 crore Sales tax ₹17.12 crore ₹12.76 crore Customs duty ₹11.24 crore ₹11.24 crore
Last updated
All 30 sources, each with its page
- 1. Annual report, 20 Jul 2026, page 99
- 2. Annual report, 20 Jul 2026, page 226
- 3. Annual report, 20 Jul 2026, page 100
- 4. Annual report, 20 Jul 2026, page 52
- 5. Annual report, 20 Jul 2026, page 253
- 6. Annual report, 20 Jul 2026, page 205
- 7. Annual report, 20 Jul 2026, page 206
- 8. Annual report, 20 Jul 2026, page 101
- 9. Annual report, 20 Jul 2026, page 40
- 10. Annual report, 20 Jul 2026, page 52
- 11. Annual report, 20 Jul 2026, page 10
- 12. Annual report, 20 Jul 2026, page 181
- 13. Annual report, 20 Jul 2026, page 41
- 14. Annual report, 20 Jul 2026, page 28
- 15. Annual report, 20 Jul 2026, page 26
- 16. Annual report, 20 Jul 2026, page 102
- 17. Annual report, 20 Jul 2026, page 103
- 18. Annual report, 20 Jul 2026, page 42
- 19. Annual report, 20 Jul 2026, page 30
- 20. Annual report, 20 Jul 2026, page 100
- 21. Annual report, 20 Jul 2026, page 226
- 22. Annual report, 20 Jul 2026, page 236
- 23. Annual report, 20 Jul 2026, page 42
- 24. Annual report, 20 Jul 2026, page 97
- 25. Annual report, 20 Jul 2026, page 111
- 26. Annual report, 20 Jul 2026, page 1
- 27. Annual report, 20 Jul 2026, page 224
- 28. Annual report, 20 Jul 2026, page 226
- 29. Annual report, 20 Jul 2026, page 226
- 30. Annual report, 20 Jul 2026, page 226
Results
Standalone; ₹ crore.Abbott India quarterly results
- Revenue growth, 12 monthsRevenue growth, 12 months. The last twelve months against the twelve before them. Left empty where the earlier figure was nought or a loss: growth out of a loss has no percentage.
- +6.3%
- Net profit growth, 12 monthsNet profit growth, 12 months. The last twelve months against the twelve before them. Left empty where the earlier figure was nought or a loss: growth out of a loss has no percentage.
- +11.2%
Quarter to Jun 2026, against the quarter before
- RevenueRevenue. The pill is the change in revenue against the quarter before: this period's figure divided by that one's, less one, in per cent.
- ₹1,814 Crup 6.09%
- Net profitNet profit. The pill is the change in net profit against the quarter before: this period's figure divided by that one's, less one, in per cent. Net profit in the glossary
- ₹429 Crup 8.51%
- Net marginNet margin. Net profit as a percentage of revenue: how much of each rupee of sales is left after every cost, interest and tax. Net margin in the glossary
- 23.6%
Revenue by quarter
Peak revenue ₹1,814 Cr, quarter to Jun 2026; lowest ₹1,605 Cr, quarter to Mar 2025
Net profit by quarter, a loss in red
| ₹ crore | Sep 2024 | Dec 2024 | Mar 2025 | Jun 2025 | Sep 2025 | Dec 2025 | Mar 2026 | Jun 2026 |
|---|---|---|---|---|---|---|---|---|
| Revenue | 1,633 | 1,614 | 1,605 | 1,738 | 1,757 | 1,724 | 1,710 | 1,814 |
| Net profit | 359 | 361 | 367 | 366 | 415 | 376 | 395 | 429 |
| Net margin | 22.0% | 22.3% | 22.9% | 21.0% | 23.6% | 21.8% | 23.1% | 23.6% |
Standalone. The last eight quarters. The latest is shaded.
Year to Mar 2026, against the year before
- RevenueRevenue. The pill is the change in revenue against the year before: this period's figure divided by that one's, less one, in per cent.
- ₹6,929 Crup 8.11%
- Net profitNet profit. The pill is the change in net profit against the year before: this period's figure divided by that one's, less one, in per cent.
- ₹1,552 Crup 9.73%
- Net margin
- 22.4%
Revenue by year
Net profit by year, a loss in red
The years either side of a change of basis do not compare. From the year to Mar 2018, GST replaced excise duty on 1 Jul 2017, and revenue before that day includes the duty.
| ₹ crore | Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | Mar 2026 |
|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | 2,939what Revenue, Mar 2017, includes. This period's revenue includes excise duty of ₹36 crore, a tax on the goods the company makes that it collects and pays to the government. | 3,307what Revenue, Mar 2018, includes. This period's revenue includes excise duty of ₹8.62 crore, a tax on the goods the company makes that it collects and pays to the government. | 3,679 | 4,093 | 4,310 | 4,919 | 5,349 | 5,849 | 6,409 | 6,929 |
| Net profit | 277 | 401 | 450 | 593 | 691 | 799 | 949 | 1,201 | 1,414 | 1,552 |
| Net margin | 9.4% | 12.1% | 12.2% | 14.5% | 16.0% | 16.2% | 17.8% | 20.5% | 22.1% | 22.4% |
Standalone. Years to March. The latest is shaded.
Business segments
In the year to Mar 2026 the company reports one business segment, Pharmaceutical, which carries all its revenue.
Valuation
Today, against the company's own history. Its history crosses a change of basis in the accounts in the year to Mar 2018: days before it are of the company before the change.Abbott India PE ratio and valuation
Price to earnings
At or below today's level on 8% of 2,478 trading days over the last 10 years.
LowestHighest
Its median47.30Industry median27.98
Price to book
At or below today's level on 14% of 1,972 trading days since Nov 2018.
LowestHighest
Its median14.90Industry median2.94
Dividend yieldDividend yield. Dividends paid per share in the twelve months to the day, as a percentage of the day's share price. When a year's dividend goes ex later than the year before's, the yield reads zero for the days between; a run of under 60 such trading days is left out of the yield's medians and percentiles. The ex-date is the day from which a buyer of the share no longer gets the dividend.
At or below today's level on 99% of 2,429 trading days over the last 10 years.
LowestHighest
Its median1.32%Industry median0.48%
Where the return came from
Yearly rates to Mar 2026, per-share figures restated for splits and bonuses.
| Over | Return a year | Earnings growth | Change in P/E | Dividend yield |
|---|---|---|---|---|
| 1 year | −13.1% | +9.7% | −23.1% | 2.5% |
| 3 years | +7.4% | +17.8% | −10.4% | 1.9% |
| 5 years | +13.3% | +17.6% | −5.1% | 1.7% |
Return is price growth plus the average dividend yield. Change in P/E is (1 + price growth) / (1 + earnings growth) - 1, so the parts compound rather than add.
Mutual fund holdings
164 funds disclosed a holding for Sep 2026. What they did in Sep 2026, against each fund's month before. 58 of the 82 funds that added or cut are index funds, ETFs or arbitrage funds: an index fund or ETF holds what its index holds, and an arbitrage fund holds the share against a sale of its future. 1 more fund filed its first portfolio on record, holding it.All 164 funds holding Abbott India
- Bought for the first timeBought for the first time. Funds that held it at the month's end and had not held it in any month on record before.
- 1
- Bought againBought again. Funds that held it at the month's end, had not held it the month before, and held it in an earlier month.
- 4
- AddedAdded. Funds that held more shares than at the end of the month before.
- 46
- CutCut. Funds that held fewer shares than at the end of the month before.
- 36
- Held unchangedHeld unchanged. Funds that held the same number of shares as at the end of the month before.
- 76
- Sold outSold out. Funds that held it at the end of the month before and hold none at this month's end. Sold out in the glossary
- 5
| Fund | |||
|---|---|---|---|
 SBI Large & Midcap FundSBI Mutual Fund | 3,08,000 | 2.06% | ₹835.5 Cr |
 Nippon India Multi Cap FundNippon India Mutual Fund | 1,47,614 | 0.74% | ₹400.4 Cr |
 Axis Midcap FundAxis Mutual Fund | 1,36,564 | 1.10% | ₹370.4 Cr |
 Canara Robeco Large and Mid Cap FundCanara Robeco Mutual Fund | 1,32,375 | 1.46% | ₹359.1 Cr |
| Nippon India Pharma FundNippon India Mutual Fund | 78,546 | 2.32% | ₹213.1 Cr |
 ICICI Prudential Healthcare FundICICI Prudential Mutual Fund | 64,361 | 2.54% | ₹174.6 Cr |
 Tata Mid Cap FundTata Mutual Fund | 50,000 | 2.31% | ₹135.6 Cr |
| Tata Large & Mid Cap FundTata Mutual Fund | 40,346 | 1.51% | ₹109.4 Cr |
| Tata India Pharma & Healthcare FundTata Mutual Fund | 33,086 | 5.94% | ₹89.7 Cr |
 PGIM India Midcap FundPGIM India Mutual Fund | 32,971 | 0.85% | ₹89.4 Cr |
Portfolios disclosed for Sep 2026. Weight is the holding as a share of the fund's assets.
Abbott India competitors and peers
Pharmaceuticals, 215 listed companies, priced on 28 Oct 2026. The table lists the 8 companies closest to Abbott India in market cap.Healthcare companies
Where the company sits among the companies nearest its size
| Company | ||||||||
|---|---|---|---|---|---|---|---|---|
 LupinLUPIN | 90,210 | 16.32 | 4.02 | +28.2% | +49.5% | 27.9% | 28.2% | 0.91% |
 Glenmark PharmaceuticalsGLENMARK | 64,912 | 36.10 | 6.17 | +32.9% | +138.4% | 18.6% | 39.8% | 0.11% |
 Alkem LaboratoriesALKEM | 60,619 | 28.10 | 4.39 | +13.4% | −5.6% | 16.7% | 16.5% | 1.05% |
 BioconBIOCON | 57,153 | 115.39 | 1.68 | +9.8% | +28.6% | 1.8% | 2.9% | 0.14% |
 Gland PharmaGLAND | 50,312 | 44.57 | 4.86 | +17.6% | +46.5% | 11.6% | 12.4% | 0.66% |
 IPCA LaboratoriesIPCALAB | 48,978 | 37.39 | 6.07 | +10.6% | +68.2% | 17.4% | 17.6% | 0.31% |
 Ajanta PharmaAJANTPHARM | 43,233 | 38.10 | 9.55 | +20.2% | +22.0% | 27.3% | 27.2% | 1.73% |
 GlaxoSmithKline PharmaceuticalsGLAXO | 42,318 | 39.62 | 18.66 | +5.8% | +12.4% | 50.6% | 56.3% | 2.28% |
Market cap in ₹ crore. Growth is the last twelve months against the twelve before. A figure is left empty where it would rest on a loss or the company has under a year of results on record. ROE is the shareholders' profit over their net worth. ROCE is profit before interest and tax over the whole group's net worth plus borrowings, as in the figures at the top of the page.
Dividends
Per share, by the year it was paid for, and the latest payments.Abbott India dividend history
Dividend per share, ₹, restated for later splits and bonuses
Dividend per share. The dividends declared for the year, each restated to today's share count by the splits and bonuses after its own ex-date, added up. Dividend per share in the glossaryHighest ₹656.00 a share, year to Mar 2026.
| Ex-date | Type | Per share |
|---|---|---|
| 24 Jul 2026 | Final | ₹525.00 |
| 24 Jul 2026 | Special | ₹131.00 |
| 25 Jul 2025 | Final | ₹475.00 |
| 19 Jul 2024 | Final | ₹410.00 |
| 21 Jul 2023 | Final | ₹180.00 |
| 21 Jul 2023 | Special | ₹145.00 |
Latest payments, as declared, by ex-date.
Latest announcements
Routine notices left out.Abbott India announcements
Oct 2026
26 Oct · Board meeting
Meeting on 5 Nov 2026: quarterly results
Sep 2026
7 Sep · Management
Aug 2026
13 Aug · Meeting
12 Aug · Results
Abbott India share price by year
Each calendar year to 2025.Abbott India share price history
| Year | Close at year end | Change | Highest close | Lowest close |
|---|---|---|---|---|
| 2025 | 29,025.00 | −2.4% | 35,670.00 | 25,501.85 |
| 2024 | 29,741.00 | +30.2% | 30,195.85 | 22,761.10 |
| 2023 | 22,851.25 | +6.9% | 24,555.80 | 20,029.15 |
| 2022 | 21,367.20 | +9.7% | 21,842.45 | 15,562.60 |
| 2021 | 19,485.65 | +23.6% | 23,184.50 | 14,093.85 |
| 2020 | 15,769.10 | +20.6% | 18,301.70 | 12,319.30 |
| 2019 | 13,075.50 | +74.0% | 13,381.80 | 7,191.05 |
| 2018 | 7,516.65 | +36.0% | 8,593.35 | 5,250.75 |
| 2017 | 5,524.95 | +17.0% | 5,643.20 | 4,022.50 |
| 2016 | 4,722.30 | −21.4% | 5,930.90 | 4,392.85 |
₹ per share, adjusted for splits and bonuses since. Change is on the close at the end of the year before.
Recent sessions
The 9 trading days to 27 Oct 2026, as traded on NSE; the latest is at the top of the page.
| Date | Open | High | Low | Close | Average price | Volume | Delivery |
|---|---|---|---|---|---|---|---|
| 27 Oct 2026 | 25,490.00 | 25,580.00 | 25,215.00 | 25,515.00 | 25,379.18 | 4,730 | 57.6% |
| 26 Oct 2026 | 25,235.00 | 25,365.00 | 24,805.00 | 25,225.00 | 25,171.63 | 3,870 | 51.3% |
| 23 Oct 2026 | 25,485.00 | 25,485.00 | 24,650.00 | 25,030.00 | 24,924.44 | 7,881 | 55.2% |
| 22 Oct 2026 | 25,795.00 | 25,795.00 | 25,275.00 | 25,360.00 | 25,410.73 | 2,397 | 46.3% |
| 21 Oct 2026 | 25,910.00 | 26,055.00 | 25,135.00 | 25,680.00 | 25,746.81 | 3,422 | 62.2% |
| 19 Oct 2026 | 26,040.00 | 26,145.00 | 25,805.00 | 25,905.00 | 25,968.03 | 2,009 | 49.5% |
| 16 Oct 2026 | 26,070.00 | 26,230.00 | 25,910.00 | 26,170.00 | 26,097.90 | 3,831 | 64.2% |
| 15 Oct 2026 | 26,290.00 | 26,290.00 | 26,000.00 | 26,070.00 | 26,126.75 | 3,195 | 47.5% |
| 14 Oct 2026 | 25,800.00 | 26,550.00 | 25,750.00 | 26,295.00 | 26,129.29 | 6,143 | 50.8% |
Prices in ₹ per share as traded, not adjusted.
Company details
- NSE symbol
- ABBOTINDIA
- BSE code
- 500488
- ISIN
- INE358A01014
- Industry
- Pharmaceuticals & Biotechnology
- Website
- www.abbott.co.in
- CIN
- L24239MH1944PLC007330
- Corporate identity number, the registrar of companies' code for it
- Incorporated
- 1944
- Registered office
- Unit No.3, Corporate Park, Sion - Trombay Road, Chembur, Mumbai 400071, Maharashtra
- Share registrar
- KFin Technologies Ltd
- Keeps the register of shareholders and handles transfers and dividend payments
In BSE 200, Nifty 500, BSE 500, Nifty Midcap 150, BSE 150 MidCap Index, BSE MidCap